コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ue, vague cognitive defects, and a low titer antinuclear antibody.
2 Three patients had a positive antinuclear antibody.
3 Sera were evaluated for the presence of antinuclear antibodies.
4 ive autoimmune B cells to produce pathogenic antinuclear antibodies.
5 , P-ANCA was associated with the presence of antinuclear antibodies.
6 mphoid organs spontaneously develop specific antinuclear antibodies.
7 thickening, and high titers of anti-DNA and antinuclear antibodies.
8 increased in humans and mice, combined with antinuclear antibodies.
9 dating autoantibody expression in SLE beyond antinuclear antibodies.
10 disease, such as arthritis, lymphopenia, or antinuclear antibodies.
11 hermore, about one-third of the mice develop antinuclear antibodies.
12 mes clinically detectable by the presence of antinuclear antibodies.
13 ), that are characterized by the presence of antinuclear antibodies.
14 c mice and was accompanied by an increase in antinuclear antibodies.
15 omenon (RP) and the presence of SSc-specific antinuclear antibodies.
16 ortion of autoreactive antibodies, including antinuclear antibodies.
17 immunofluorescence studies that demonstrate antinuclear antibodies.
18 tis and small joint involvement, and express antinuclear antibodies.
19 ts produced in vitro anti-GBM antibodies and antinuclear antibodies.
20 the majority of MZ twins are concordant for antinuclear antibodies.
21 cular dryness in the presence of circulating antinuclear antibodies.
23 fold capillaroscopy and laboratory tests for antinuclear antibodies (ANA) and ANA subsets were obtain
24 indirect immunofluorescence assays to detect antinuclear antibodies (ANA) and antineutrophil cytoplas
25 ficient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulonephriti
26 in children may be associated with positive antinuclear antibodies (ANA) and may progress to systemi
27 say were compared with those of an assay for antinuclear antibodies (ANA) and with the severity of th
29 Screening only for antibodies to actin and antinuclear antibodies (ANA) failed to establish the dia
30 cted mixtures in relation to the presence of antinuclear antibodies (ANA), a widely used biomarker of
31 A majority of these autoantibodies are true antinuclear antibodies (ANA), and 50% of the ANAs are al
32 active protein, leukocyte count, presence of antinuclear antibodies (ANA), presence of human leukocyt
34 A locus Adnz1 on chromosome 4 was linked to antinuclear antibody (ANA) and anti-double stranded DNA
36 suggests that patients with in vivo speckled antinuclear antibody (ANA) patterns have high titers of
37 associations between mercury biomarkers and antinuclear antibody (ANA) positivity and titer strength
38 IA patients, including female preponderance, antinuclear antibody (ANA) positivity, and certain human
39 three positive answers were to attend for an antinuclear antibody (ANA) test; and those testing posit
40 orescence methods with bead-based assays for antinuclear antibody (ANA) testing is a new clinical opt
42 A were identified, and serologic studies for antinuclear antibody (ANA), rheumatoid factor, and antib
43 DNA) and double-stranded DNA (anti-dsDNA) in antinuclear antibody (ANA)-positive type 1 autoimmune he
44 ic arthritis, spinal pain, fever, psoriasis, antinuclear antibodies [ANA], and rheumatoid factor).
45 E Disease Activity Index (SLEDAI), serology (antinuclear antibody [ANA] and anti-double-stranded (ds)
46 case-control study confirmed the presence of antinuclear antibodies (ANAs) and other autoantibodies i
50 nt (SLC-/-) mice harbored elevated levels of antinuclear antibodies (ANAs) in their serum and showed
51 s (SLE) is characterized by high-avidity IgG antinuclear antibodies (ANAs) that are almost certainly
52 ototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes
55 -12 survey), laboratory parameters including antinuclear antibodies (ANAs), and SARS-CoV-2 antibody l
56 ti-citrullinated protein antibodies (ACPAs), antinuclear antibodies (ANAs), anti-tissue transglutamin
57 ototypic autoimmune disease characterized by antinuclear antibodies (ANAs), including pathogenic spec
58 bers according to the presence or absence of antinuclear antibodies (ANAs), the ANA staining patterns
63 els, E6446 slowed development of circulating antinuclear antibodies and had a modest effect on anti-d
64 omparable in patients with and those without antinuclear antibodies and in both early- and late-onset
65 Female NZB/WF1 mice produce high titers of antinuclear antibodies and invariably succumb to severe
66 between fibromyalgia patients with low titer antinuclear antibodies and primary SS remains difficult.
68 itis, and laboratory abnormalities including antinuclear antibody and rheumatoid factor positivity.
69 SLE was based on the presence of arthritis, antinuclear antibodies, and double-stranded DNA, and a c
71 ted diagnoses, discoid lupus, positivity for antinuclear antibodies, and/or false-positive syphilis t
73 presence of EBOV-specific immunoglobulin G, antinuclear antibodies, anti-cyclic citrullinated peptid
74 udies were similar, including positivity for antinuclear antibodies, anti-native DNA, and anti-double
75 ion markers included (1) autoimmunity signs (antinuclear antibody, antihistone antibody, antithyroglo
78 etric analysis of salivary glands, and serum antinuclear antibody assay were performed to assess vari
81 ed with the presence of rheumatoid factor or antinuclear antibodies, but not with positive allergen s
84 Loci linked with anti-gp70 compared with antinuclear antibodies demonstrated the strongest linkag
86 en patients with (Ab(+)) and without (Ab(-)) antinuclear antibody during adulthood and an age- and se
89 ss offspring uncovered 5 suggestive loci for antinuclear antibody formation, consisting of 3 dominant
91 regimen eluted severalfold more IgG and IgM antinuclear antibodies from the kidneys of nephritic SNF
92 n(KO) mice is characterized by production of antinuclear antibodies, glomerulonephritis, impaired B c
93 et of 321 serologically active SLE patients (antinuclear antibodies >/=1:80 and/or anti-double-strand
94 ly, H2(d/z) (compared with H2(d/d)) enhanced antinuclear antibodies in a coordinate fashion but did n
95 ther compounded by the finding of "positive" antinuclear antibodies in a high percent of the general
96 ssociations between selected xenobiotics and antinuclear antibodies in the National Health and Nutrit
97 hocytic infiltration of the lacrimal glands, antinuclear antibodies in the serum, and elevated titer
98 serum anti-CCP, rheumatoid factor (RF), and antinuclear antibody in a defined sample of 9,988 of bla
100 positive results because of the presence of antinuclear antibodies, is not a specific marker of anti
103 ers such as serum immunoglobulin G (IgG) and antinuclear antibody levels were available in 12 patient
104 active protein level, rheumatoid factor, and antinuclear antibody levels were within normal limits.
105 ith DSRD were more likely to have a positive antinuclear antibody, low complement 3, abnormal cytokin
106 Sera were tested using immunofluorescent antinuclear antibodies on HEp-2 cell slides, by anti-RNA
107 -like syndrome with joint manifestations and antinuclear antibodies: one had anti-RNP and antiphospho
108 sy-proven lupus nephritis in the presence of antinuclear antibodies or anti-double-stranded DNA antib
109 n-experienced autoreactive B cells producing antinuclear antibody or rheumatoid factor and exhibit th
111 )/L: OR 2.15, 95% CI 1.63-2.83), presence of antinuclear antibodies (OR 2.87, 95% 1.57-5.24), and tre
112 ficantly associated with: i/ the presence of antinuclear antibodies (OR=5.9, P=0.04) ii/ a more sever
114 fferences in EBOV-specific immunoglobulin G, antinuclear antibody, or anti-cyclic citrullinated pepti
116 before the diagnosis, were found later than antinuclear antibodies (P=0.06) and earlier than anti-nu
117 e weakness and congestive heart failure, was antinuclear antibody positive and had muscle biopsy find
119 on between the effects of rheumatoid factor, antinuclear antibodies, positive skin allergen tests, or
121 r, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DN
123 most frequent combination was arthritis and antinuclear antibody positivity followed by malar rash a
126 subjects in this cohort had similar rates of antinuclear antibody positivity, whereas lupus-specific
129 dermatomyositis, the mice developed a strong antinuclear antibody response, characteristic of autoimm
130 ash, autoimmune thyroiditis, the presence of antinuclear antibodies, sinopulmonary infections, and co
132 range of autoantibodies (rheumatoid factor, antinuclear antibody, smooth muscle autoantibody, mitoch
138 ccordingly, the positive predictive value of antinuclear antibody testing in diagnosing SLE in a pati
139 is needed to establish the value of routine antinuclear antibody testing in patients with uveitis.
140 The positive predictive value of routine antinuclear antibody testing was 2.9% (95% CI, 2.65%-3.1
142 e negative for anti-SSA/Ro, anti-SSB/La, and antinuclear antibodies than women (36% men vs 11% women,
143 up (71.5%) of serologically active patients (antinuclear antibody titer >/=1:80 and/or anti-double-st
144 ents with lcSSc or Raynaud's syndrome and an antinuclear antibody typical of lcSSc as part of the bas
145 elet volume, positive rheumatoid factor, and antinuclear antibodies were all significantly more preva
146 s syndrome with high levels of antineural or antinuclear antibodies were infused bilaterally into the
153 s with systemic autoimmune disease featuring antinuclear antibodies with IgG4 elevation uncovered an